Pancreatic Cancer Research

ResearcherChinese Academy of Medical Sciences & Peking Union Medical CollegeActive in the last 2 years

Yueze Liu

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0001-8163-9129; OpenAlex author ID A5102007990. Sources: OpenAlex.

Their work

Papers
23 (first author 1, last author 0)
Trials
0
Grants
0
Labs led
0
Collaborators
39
Papers, trials and grants by year

2019: 3 papers · 2020: 4 papers · 2021: 3 papers · 2022: 1 paper · 2023: 6 papers · 2024: 4 papers · 2025: 1 paper · 2026: 1 paper

Papers 23

  1. TRDMT1-mediated mRNA m5C methylation decreases chemotherapy sensitivity by activating homologous recombination-mediated DNA damage repair and IRS2 expression i… Co-author DOI 10.1016/j.canlet.2026.218725↗
  2. SPP1+ Venous Endothelial Cells and CRABP2+ Tumor Cells Contribute to Favorable Body and Tail Pancreatic Ductal Adenocarcinoma Tumor Microenvironment. Co-author DOI 10.1002/mc.23936↗
  3. E3 ubiquitin ligase RBCK1 confers ferroptosis resistance in pancreatic cancer by facilitating MFN2 degradation. Co-author DOI 10.1016/j.freeradbiomed.2024.05.031↗
  4. The NF-κB/NUAK2 signaling axis regulates pancreatic cancer progression by targeting SMAD2/3. Co-author DOI 10.1016/j.isci.2024.109406↗
  5. FBXO32 Stimulates Protein Synthesis to Drive Pancreatic Cancer Progression and Metastasis. Co-author DOI 10.1158/0008-5472.can-23-3638↗
  6. Human Equilibrative Nucleoside Transporter 1: Novel Biomarker and Prognostic Indicator for Patients with Gemcitabine-Treated Pancreatic Cancer. Co-author DOI 10.2147/cmar.s465098↗
  7. Genomic analysis and filtration of novel prognostic biomarkers based on metabolic and immune subtypes in pancreatic cancer. First author DOI 10.1007/s13402-023-00836-3↗
  8. mTOR inhibitor, gemcitabine and PD-L1 antibody blockade combination therapy suppresses pancreatic cancer progression via metabolic reprogramming and immune mic… Co-author DOI 10.1016/j.canlet.2022.216020↗
  9. Novel strategies optimize immunotherapy by improving the cytotoxic function of T cells for pancreatic cancer treatment. Co-author DOI 10.1016/j.canlet.2023.216423↗
  10. PRKRA promotes pancreatic cancer progression by upregulating MMP1 transcription via the NF-κB pathway. Co-author DOI 10.1016/j.heliyon.2023.e17194↗
  11. Using a microRNA panel of circulating exosomes for diagnosis of pancreatic cancer: multicentre case-control study. Co-author DOI 10.1093/bjs/znac375↗
  12. Epidemiology of pancreatic cancer: New version, new vision. Co-author DOI 10.21147/j.issn.1000-9604.2023.05.03↗
  13. HIF-1α-regulated stanniocalcin-1 mediates gemcitabine resistance in pancreatic ductal adenocarcinoma via PI3K/AKT signaling pathway. Co-author DOI 10.1002/mc.23420↗
  14. CREPT serves as a biomarker of poor survival in pancreatic ductal adenocarcinoma. Co-author DOI 10.1007/s13402-020-00569-7↗
  15. Integrative Genomic Analysis of Gemcitabine Resistance in Pancreatic Cancer by Patient-derived Xenograft Models. Co-author DOI 10.1158/1078-0432.ccr-19-3975↗
  16. The Role of Mitochondria in the Chemoresistance of Pancreatic Cancer Cells. Co-author DOI 10.3390/cells10030497↗
  17. Mechanistic target of rapamycin in the tumor microenvironment and its potential as a therapeutic target for pancreatic cancer. Co-author DOI 10.1016/j.canlet.2020.05.003↗
  18. Novel Discoveries Targeting Pathogenic Gut Microbes and New Therapies in Pancreatic Cancer: Does Pathogenic E. coli Infection Cause Pancreatic Cancer Progressi… Co-author DOI 10.1155/2020/2340124↗
  19. OLR1 Promotes Pancreatic Cancer Metastasis via Increased c-Myc Expression and Transcription of HMGA2. Co-author DOI 10.1158/1541-7786.mcr-19-0718↗
  20. Novel therapeutic strategies and perspectives for metastatic pancreatic cancer: vaccine therapy is more than just a theory. Co-author DOI 10.1186/s12935-020-1147-9↗
  21. Novel discoveries targeting gemcitabine-based chemoresistance and new therapies in pancreatic cancer: How far are we from the destination? Co-author DOI 10.1002/cam4.2384↗
  22. Role of the microbiome in occurrence, development and treatment of pancreatic cancer. Co-author DOI 10.1186/s12943-019-1103-2↗
  23. Low hENT1 expression indicates poor prognosis in gemcitabine-treated pancreatic cancer patients Co-author DOI 10.21203/rs.2.17850/v1↗

Closest collaborators

The 25 strongest of 39 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Taiping Zhang · 22 shared papers, 2019–2025 · strength 3.24
  2. Jiangdong Qiu · 14 shared papers, 2019–2025 · strength 2.23
  3. Wenhao Luo · 14 shared papers, 2019–2026 · strength 2.22
  4. Lei You · 14 shared papers, 2019–2026 · strength 1.86
  5. Jinxin Tao · 10 shared papers, 2022–2025 · strength 1.78
  6. Fangyu Zhao · 14 shared papers, 2019–2024 · strength 1.78
  7. Gang Yang · 13 shared papers, 2019–2024 · strength 1.72
  8. Zhe Cao · 12 shared papers, 2019–2024 · strength 1.52
  9. Jianchun Xiao · 8 shared papers, 2019–2026 · strength 1.23
  10. Dan Su · 6 shared papers, 2022–2024 · strength 1.03
  11. Jiangdong Qiu · 8 shared papers, 2019–2024 · strength 1.01
  12. Guangyu Chen · 7 shared papers, 2020–2024 · strength 1.00
  13. Ruobing Wang · 5 shared papers, 2023–2024 · strength 0.93
  14. Yupei Zhao · 8 shared papers, 2019–2023 · strength 0.90
  15. Mengyu Feng · 7 shared papers, 2019–2023 · strength 0.88
  16. Hua Huang · 4 shared papers, 2021–2025 · strength 0.67
  17. Jun Wang · 3 shared papers, 2023–2025 · strength 0.53
  18. Gang Yang · 3 shared papers, 2019–2024 · strength 0.46
  19. Zhe Cao · 2 shared papers, 2025–2026 · strength 0.43
  20. Yifan Fu · 2 shared papers, 2025–2026 · strength 0.43
  21. Yuanyang Wang · 2 shared papers, 2024–2025 · strength 0.39
  22. Guangbing Xiong · 3 shared papers, 2020–2023 · strength 0.37
  23. Yupei Zhao · 1 shared paper, 2026 · strength 0.24
  24. Yuanyang Wang · 1 shared paper, 2026 · strength 0.24
  25. Tao Liu · 1 shared paper, 2025 · strength 0.20

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.